Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14854988 | 0.85 | NPSR1 (0.35) | NPSR1SIGMAR1 | |
| SCHEMBL21664697 | 0.77 | NPSR1 (0.41) | NPSR1USP2PAOXLMNAALDH1A1 | |
| SCHEMBL20754833 | 0.77 | MAOB (0.52) | KDM4E | |
| SCHEMBL918207 | 0.76 | NPSR1 (0.50) | NPSR1USP2PAOXLMNAALDH1A1 | |
| SCHEMBL3903877 | 0.76 | NPSR1 (0.41) | NPSR1USP2PAOXLMNAALDH1A1 | |
| SCHEMBL3903880 | 0.76 | NPSR1 (0.46) | NPSR1USP2PAOXLMNAALDH1A1 | |
| SCHEMBL15675036 | 0.75 | ALDH1A1 (0.43) | ALDH1A1 | |
| Water SCHEMBL21295559 | 0.74 | NPSR1 (0.48) | NPSR1USP2PAOXLMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL7099693 | 0.73 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL21664792 | 0.72 | NPSR1 (0.36) | NPSR1PAOXALDH1A1SIGMAR1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152232-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF | SAUNDERS JEFFREY O | 2011-06-23 | — | — | US | disclosed |
| US-20110152232-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF | SAUNDERS JEFFREY O | 2011-06-23 | — | — | US | disclosed |
| US-20110152232-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF | SAUNDERS JEFFREY O | 2011-06-23 | — | — | US | disclosed |
| US-7829589-B2 | Sulfonamide compounds and uses thereof | ELIXIR PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829589-B2 | Sulfonamide compounds and uses thereof | ELIXIR PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829589-B2 | Sulfonamide compounds and uses thereof | ELIXIR PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| WO-2010104929-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| EP-1893569-A4 | SULFONAMIDE COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008141189-A1 | GHRELIN MODULATING COMPOUNDS AND COMBINATIONS THEREOF | ELIXIR PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141189-A1 | GHRELIN MODULATING COMPOUNDS AND COMBINATIONS THEREOF | ELIXIR PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| EP-1893569-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF | Elixir Pharmaceuticals, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070270473-A1 | Sulfonamide Compounds and Uses Thereof | ELIXIR PHARMACEUTICALS, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270473-A1 | Sulfonamide Compounds and Uses Thereof | ELIXIR PHARMACEUTICALS, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270473-A1 | Sulfonamide Compounds and Uses Thereof | ELIXIR PHARMACEUTICALS, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20060293370-A1 | Sulfonamide compounds and uses thereof | ELIXIR PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006135860-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293370-A1 | Sulfonamide compounds and uses thereof | GHSR, GHRHR, SSTR2 | NPSR1 23/4885USP2 1469/4885APAF1 4499/4885 |
| US-20070270473-A1 | Sulfonamide Compounds and Uses Thereof | GHSR, GHRHR, SSTR2 | NPSR1 23/4885USP2 1469/4885APAF1 4499/4885 |
| US-20110152232-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF | GHSR, GHRHR, SSTR2 | NPSR1 23/4885USP2 1469/4885APAF1 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.